GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (LTS:0QAJ) » Definitions » Cash Receipts from Loans

DBV Technologies (LTS:0QAJ) Cash Receipts from Loans


View and export this data going back to 2015. Start your Free Trial

What is DBV Technologies Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.


DBV Technologies Business Description

Traded in Other Exchanges
Address
107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.